Gsk (GSK) Divestments (2009 - 2026)

Gsk (GSK) has 18 years of Divestments data on file, last reported at $349.1 million in Q3 2026.

• For the quarter ending Q3 2026, Divestments changed N/A year-over-year to $349.1 million; the trailing twelve-month figure through Sep 2026 stood at $639.6 million (changed N/A YoY), and the FY2025 full-year result was -$35.9 million, down 56.09% from the prior year.
• Divestments was $349.1 million for Q3 2026 at Gsk, up from $330.3 million in the prior quarter.
• In the past five years, Divestments ranged from a high of $349.1 million in Q3 2026 to a low of -$38.6 million in Q4 2025.
• A 5-year average of $67.5 million and a median of -$2.5 million in 2024 frame the typical range for Divestments.
• Across the five-year window, Divestments slumped 643.51% in 2023 and surged 26324.98% in 2026, its largest moves.
• Gsk's Divestments stood at -$14.1 million in 2022, then jumped by 611.45% to $72.0 million in 2023, then sank by 117.83% to -$12.8 million in 2024, then plunged by 200.54% to -$38.6 million in 2025, then soared by 1004.96% to $349.1 million in 2026.
• Per Business Quant data, the three most recent Divestments figures were $349.1 million in Q3 2026, $330.3 million in Q1 2026, and -$38.6 million in Q4 2025.